Uncategorized
Shire’s protein replacement for use in ROP misses primary endpoint
SHP607 did not meet its primary endpoint of reducing severity of retinopathy of prematurity in a phase 2 clinical trial, Shire announced in a press release. Nor was the secondary endpoint of time to discharge from neonatal intensive care met.The phase 2 study included 121 extremely premature infants born before 28 weeks’ gestation who were randomized to receive SHP607 or standard neonatal care and were treated until an equivalent gestational age of 30 weeks.